A CRISPR-based technology to treat cytomegalovirus (CMV) and other Viral Infections.
Generated by a Claude Opus 4.7 agent (max thinking effort, 1M-context). Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Cytomegalovirus (CMV) and other viral infections
Modality
Gene Therapy
Mechanism
CRISPR/Cas9 antiviral
Target
CMV IE1
rNPV Envelope
Low
-$68.9M
costs +25% · peak −25%
Base
-$44.4M
cumulative PoS 6.4%
High
-$19.9M
costs −25% · peak +25%
CMV CRISPR is modeled as gene therapy with antiviral proof-of-concept and delivery risk, not as a standard small molecule. Letermovir and maribavir anchor the market and trial endpoints, while legacy antivirals frame the toxicity/resistance gap.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.75
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.672 — composite-score rank #6 of 10 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#6) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
PREVYMIS (Merck) — letermovir
Launched CMV prophylaxis benchmark in transplant patients and clearest revenue anchor.
Criteria 2: same CMV transplant market with launched antiviral revenue benchmark.
LIVTENCITY (Takeda) — maribavir
Approved CMV treatment for refractory/resistant disease, closer to unmet-need positioning.
Criteria 2 and 3: same CMV serious-disease pathway and resistant/refractory clinical niche.
Ganciclovir/foscarnet (legacy antivirals)
Legacy CMV standards define toxicity and resistance gaps for a gene-targeted antiviral.
Criteria 2: same indication legacy standard-of-care, used to frame differentiation rather than revenue.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $20.0M | 24 mo | 45.0% | [0] [2] [4] |
| Phase I | $65.0M | 18 mo | 66.0% | [1] [4] [5] |
| Phase II | $140.0M | 30 mo | 42.0% | [0] [1] [5] |
| Phase III | $220.0M | 30 mo | 58.0% | [0] [1] [5] |
| NDA/BLA Review | $15.0M | 12 mo | 88.0% | [0] [1] [5] |
Multiplier handling: Eligible multipliers (gene_therapy_1.41x, fast_track_or_rmat) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$350.0M peak · WACC 14.0%
Peak revenue. PREVYMIS supports a meaningful CMV prophylaxis market, but a CRISPR antiviral would initially target refractory, transplant, or high-risk niches due to delivery and safety constraints. The $350M peak places it above a narrow salvage product but below broad prophylaxis penetration.
WACC. In vivo antiviral editing and delivery risk point toward pharma partnership economics rather than low-risk standalone financing.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$44.4M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$203.9M
P25
-$81.4M
P50 (median)
-$23.5M
P75
-$12.6M
P95
$66.7M
Prob ≥ 0
5.5%
Comparable launch curves
Revenue trajectories of named comparators
PREVYMIS (Merck) — letermovir
Launched 2017 · peak $760.0M (estimated)
Evidence register
6 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
PREVYMIS revenue and CMV market anchor comparators[0] | Merck fourth-quarter and full-year 2024 financial results company_filing | 2025-02-04 | high |
LIVTENCITY approval comparator comparators[1] | Takeda: LIVTENCITY approved by U.S. FDA regulatory | 2021-11-23 | high |
Ganciclovir legacy comparator comparators[2] | NCI Drug Dictionary: ganciclovir regulatory | 2025-01-01 | high |
Foscarnet legacy comparator comparators[2].selection_criteria | NCI Drug Dictionary: foscarnet sodium regulatory | 2025-01-01 | high |
Gene-therapy antiviral cost bounds stage_profile.phase_1.cost_usd_m | Wouters et al., Estimated R&D Investment Needed to Bring a New Medicine to Market, JAMA 2020 peer_review | 2020-03-03 | medium |
Antiviral/gene-therapy PoS sanity stage_profile.phase_2.pos | BIO/QLS/Informa Clinical Development Success Rates 2011-2020 peer_review | 2021-02-17 | medium |
Thesis
Why this asset earns its top-10 rank
The CMV CRISPR asset addresses a clear virology problem: existing antivirals suppress CMV but do not remove latent or refractory viral reservoirs, and toxicity/resistance remain problems in transplant patients. The top-10 ranking is driven by clinical relevance, a differentiated antiviral mechanism, and a plausible platform extension to other viral genomes.
PREVYMIS gives the launched prophylaxis revenue anchor, LIVTENCITY frames refractory post-transplant disease, and ganciclovir/foscarnet define the legacy toxicity gap. The engine result is -$68.9M to -$19.9M, with a base rNPV of -$44.4M and cumulative PoS of 6.4%; that supports a partnership-candidate interpretation, because CRISPR antiviral delivery and safety risk are too high for a simple small-molecule-style standalone path.
The verdict is a strategically interesting antiviral gene-therapy concept. It belongs in the top 10 because the mechanism is differentiated and the CMV market is real, but the value depends on a pharma partner that can solve delivery, safety, and transplant-study execution.
Key risks
Asset-specific, not generic biotech risks
- CRISPR delivery to CMV-infected or latent reservoirs may be insufficient for clinical clearance.
- Viral sequence diversity could create escape from a single guide strategy.
- Off-target editing risk is harder to tolerate in prophylactic transplant settings.
- Small-molecule antivirals set a lower-cost standard that may limit premium pricing.